-+ 0.00%
-+ 0.00%
-+ 0.00%

Evaxion Announces Final Patient Visit In One-Year Extension Phase 2 Trial Of Personalized Melanoma Cancer Vaccine EVX-01

Benzinga·04/07/2026 12:10:35
Listen to the news

EVX-01 is a personalized cancer vaccine currently being evaluated as a treatment for advanced melanoma (skin cancer). In the first two years of the phase 2 trial, patients were treated with EVX-01 in combination with MSD's (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy, Keytruda® (pembrolizumab).